

PRESS RELEASE

30 May 2023 13:04:00 CEST

Senzime expands partnership with Japanese licensee and starts system deliveries

Uppsala, May 30, 2023. Senzime AB (publ) today announced an expanded collaboration with Japanese licensee Fukuda Denshi to also include the manufacturing of TetraGraph systems. Through the new agreement, Senzime has taken over production responsibility from previous external suppliers. The first order now delivered to Fukuda Denshi in Japan includes 30 TetraGraph systems.

Fukuda Denshi Co. Ltd is a world leader in the patient monitoring market and has a license agreement with Senzime since 2016. The agreement grants Fukuda Denshi exclusive rights to license and commercialize Senzime's TetraGraph technology under its own brand at the Japanese market.

Fukuda Denshi has previously purchased components directly from Senzime's appointed external suppliers. Since Senzime now has its own manufacturing facility in Uppsala, which is approved by both MDR and FDA, the collaboration with Fukuda has now been expanded to also include manufacturing and delivery of systems. The new agreement will also generate revenue for Senzime on manufactured products, in addition to the previous variable royalty fee based on actual sales in Japan.

"Strategic partnerships with leading global companies is a clear strategy for Senzime and the collaboration with Fukuda Denshi is an example of this. Together, we have the right conditions to increase patient safety for millions of patients in Japan. I am expecting continued success in the collaboration between our companies," commented Philip Siberg, CEO at Senzime.

In Japan, over 2.7 million major operations are performed annually in approximately 13,500 operating rooms. Senzime's TetraGraph is a system used to monitor patients undergoing anesthesia to guide anesthesiologists in ensuring the correct dose of paralytic drugs and indicate when it is safe for the patient to breathe spontaneously again. The TetraGraph system is based on a proprietary algorithm based on electromyography (EMG) which enables accurate monitoring of a patient's muscle potential in real time.

For further information, please contact:

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Sensime

Sensime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Sensime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Sensime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at sensime.com.

Attachments

Sensime expands partnership with Japanese licensee and starts system deliveries